Literature DB >> 17025275

Protein aggregation and bioprocessing.

Mary E M Cromwell1, Eric Hilario, Fred Jacobson.   

Abstract

Protein aggregation is a common issue encountered during manufacture of biotherapeutics. It is possible to influence the amount of aggregate produced during the cell culture and purification process by carefully controlling the environment (eg, media components) and implementing appropriate strategies to minimize the extent of aggregation. Steps to remove aggregates have been successfully used at a manufacturing scale. Care should be taken when developing a process to monitor the compatibility of the equipment and process with the protein to ensure that potential aggregation is minimized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17025275      PMCID: PMC2761064          DOI: 10.1208/aapsj080366

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  18 in total

Review 1.  Pathways for protein disulphide bond formation.

Authors:  A R Frand; J W Cuozzo; C A Kaiser
Journal:  Trends Cell Biol       Date:  2000-05       Impact factor: 20.808

2.  Protein aggregation during overexpression limited by peptide extensions with large net negative charge.

Authors:  Yian-Biao Zhang; Jason Howitt; Sean McCorkle; Paul Lawrence; Karen Springer; Paul Freimuth
Journal:  Protein Expr Purif       Date:  2004-08       Impact factor: 1.650

Review 3.  Effects of protein aggregates: an immunologic perspective.

Authors:  Amy S Rosenberg
Journal:  AAPS J       Date:  2006-08-04       Impact factor: 4.009

4.  Linear scale ultrafiltration.

Authors:  R van Reis; E M Goodrich; C L Yson; L N Frautschy; S Dzengeleski; H Lutz
Journal:  Biotechnol Bioeng       Date:  1997-09-05       Impact factor: 4.530

5.  Dityrosine: a marker for oxidatively modified proteins and selective proteolysis.

Authors:  C Giulivi; K J Davies
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

6.  Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor.

Authors:  J M Moore; T W Patapoff; M E Cromwell
Journal:  Biochemistry       Date:  1999-10-19       Impact factor: 3.162

7.  Effective elution of antibodies by arginine and arginine derivatives in affinity column chromatography.

Authors:  Daisuke Ejima; Ryosuke Yumioka; Kouhei Tsumoto; Tsutomu Arakawa
Journal:  Anal Biochem       Date:  2005-10-15       Impact factor: 3.365

8.  Manufacture and quality control of CAMPATH-1 antibodies for clinical trials.

Authors:  J Phillips; A Drumm; P Harrison; P Bird; K Bhamra; E Berrie; G Hale
Journal:  Cytotherapy       Date:  2001       Impact factor: 5.414

9.  Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations.

Authors:  James D Andya; Chung C Hsu; Steven J Shire
Journal:  AAPS PharmSci       Date:  2003

10.  Free sulfhydryl in recombinant monoclonal antibodies.

Authors:  Wei Zhang; Marta J Czupryn
Journal:  Biotechnol Prog       Date:  2002 May-Jun
View more
  137 in total

1.  Structure and function of purified monoclonal antibody dimers induced by different stress conditions.

Authors:  Rajsekhar Paul; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Hermann Beck; Alexandre Briguet; Volker Schnaible; Thomas Buckel; Sabine Boeckle
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

2.  Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis.

Authors:  Xiaoling Wang; Satish K Singh; Sandeep Kumar
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

3.  The use of native cation-exchange chromatography to study aggregation and phase separation of monoclonal antibodies.

Authors:  Shuang Chen; Hollis Lau; Yan Brodsky; Gerd R Kleemann; Ramil F Latypov
Journal:  Protein Sci       Date:  2010-06       Impact factor: 6.725

4.  Insert engineering and solubility screening improves recovery of virus-like particle subunits displaying hydrophobic epitopes.

Authors:  R S Abidin; L H L Lua; A P J Middelberg; F Sainsbury
Journal:  Protein Sci       Date:  2015-10-07       Impact factor: 6.725

5.  Conformational Analysis of Proteins in Highly Concentrated Solutions by Dialysis-Coupled Hydrogen/Deuterium Exchange Mass Spectrometry.

Authors:  Damian Houde; Zeinab E Nazari; George M Bou-Assaf; Andrew S Weiskopf; Kasper D Rand
Journal:  J Am Soc Mass Spectrom       Date:  2016-02-09       Impact factor: 3.109

6.  Ion-specific modulation of protein interactions: anion-induced, reversible oligomerization of a fusion protein.

Authors:  Yatin R Gokarn; R Matthew Fesinmeyer; Atul Saluja; Shawn Cao; Jane Dankberg; Andrew Goetze; Richard L Remmele; Linda O Narhi; David N Brems
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

7.  Characterization of Aggregation Propensity of a Human Fc-Fusion Protein Therapeutic by Hydrogen/Deuterium Exchange Mass Spectrometry.

Authors:  Richard Y-C Huang; Roxana E Iacob; Stanley R Krystek; Mi Jin; Hui Wei; Li Tao; Tapan K Das; Adrienne A Tymiak; John R Engen; Guodong Chen
Journal:  J Am Soc Mass Spectrom       Date:  2016-08-15       Impact factor: 3.109

8.  Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab).

Authors:  Bas J M Peters; Martinus A H Capelle; Tudor Arvinte; Ewoudt M W van de Garde
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

Review 9.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  A bayesian approach for quantifying trace amounts of antibody aggregates by sedimentation velocity analytical ultracentrifugation.

Authors:  Patrick H Brown; Andrea Balbo; Peter Schuck
Journal:  AAPS J       Date:  2008-09-24       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.